63 completed, 24 terminated, 13 active not recruiting, 7 recruiting. 48 Phase 2, 45 Not applicable, 11 Phase 1, 8 Phase 3, 5 Early Phase 1.
Follow Stage II Breast Cancer: new trials by email Literature Review of Stage II Breast Cancer trials Research Report on Stage II Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Researching the Effect of Exercise on Cancer Exercise - Breast Cancer, Prostate Cancer | Not applicable | Recruiting | City of Hope Medical Center | 51 | 2026-10-30 | 2026-08-27 |
| Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET) MINDSET, Enhanced Usual Care (EUC) - Depression, Cancer | Not applicable | Not yet recruiting | Case Comprehensive Cancer Center | 76 | 2026-08-03 | 2026-01-23 |
| SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response SHR-A1811 - Early Breast Cancer, HER2 + Breast Cancer | Phase 2 | Not yet recruiting | Chuan Wang | 30 | 2025-10-01 | 2025-08-26 |
| A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients. Magic Ink - Ductal Carcinoma in Situ, Stage I Breast Cancer | Not applicable | Recruiting | Barbara Ann Karmanos Cancer Institute | 30 | 2025-08-18 | 2025-09-18 |
| A Study of Revaree Plus in People With Breast Cancer Revaree Plus - Breast Cancer, Stage 0 Breast Cancer | Phase 4 | Recruiting | Memorial Sloan Kettering Cancer Center | 60 | 2025-06-20 | 2026-02-06 |
| Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment Breast Cancer Female, Stage II Breast Cancer | Recruiting | Gene Solutions | 125 | 2023-09-16 | 2025-09-23 | |
| TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients THRIVE, Health Education Support Program - Breast Cancer, Stage III Breast Cancer | Not applicable | Recruiting | Dana-Farber Cancer Institute | 270 | 2023-03-20 | 2026-07-17 |
| Improving Exercise Capacity With a Tailored Physical Activity Intervention Exercise with Trainerize application, Cardiopulmonary exercise testing, MRI scan - Non Hodgkin Lymphoma, Heart; Functional Disturbance | Not applicable | Active not recruiting | Wake Forest University Health Sciences | 105 | 2023-03-01 | 2026-09-09 |
| Partial Chest Wall Radiation Therapy After Surgery for Lymph Node Negative Breast Cancer Partial Chest Wall Radiation Therapy - Breast Cancer, Breast Cancer Female | Early Phase 1 | Withdrawn | Stony Brook University | 2022-07-15 | 2023-10-18 | |
| Comparison Between Prepectoral and Subpectoral Breast Reconstruction The breast reconstruction method after single-port insufflation endoscopic nipple-sparing mastectomy - Stage II Breast Cancer, Stage I Breast Cancer | Recruiting | Beijing Friendship Hospital | 88 | 2022-03-01 | 2023-04-27 | |
| Ask Questions (ASQ):Implementation of a Communication Intervention Behavioral Intervention - Stage II Breast Cancer, Stage III Breast Cancer | Not applicable | Completed | Barbara Ann Karmanos Cancer Institute | 81 | 2021-08-25 | 2023-08-16 |
| Niraparib + Dostarlimab In BRCA Mutated Breast Cancer Niraparib, Dostarlimab - Stage I Breast Cancer, Stage II Breast Cancer | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 66 | 2021-01-21 | 2026-09-24 |
| Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer Anastrozole, Therapeutic Conventional Surgery, Trastuzumab Deruxtecan - Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 88 | 2020-10-09 | 2025-11-10 |
| MARGetuximab Or Trastuzumab (MARGOT) Paclitaxel, Pertuzumab, Margetuximab - Breast Cancer, Stage II Breast Cancer | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 174 | 2020-07-13 | 2025-11-18 |
| Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03 TX05 (trastuzumab), Herceptin (trastuzumab) - HER2-positive Breast Cancer, Early-stage Breast Cancer | Phase 3 | Completed | Tanvex BioPharma USA, Inc. | 338 | 2019-08-20 | 2022-10-26 |
| Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer Exercise Intervention, Informational Intervention, Laboratory Biomarker Analysis - Cancer Survivor, Central Obesity | Not applicable | Withdrawn | University of Southern California | 2019-07-29 | 2019-10-24 | |
| Acupuncture Pilot Study for Cancer-related Cognitive Function Acupuncture, Sham Acupuncture, 16 week waiting period + optional Acupuncture - Stage I Breast Cancer, Stage II Breast Cancer | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 48 | 2019-07-01 | 2026-08-12 |
| Living Well After Breast Surgery Breast reconstruction decision aid, Educational website - Breast Cancer Female, Stage I Breast Cancer | Not applicable | Completed | University of Texas at Austin | 17 | 2019-02-18 | 2021-11-02 |
| Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA] - Breast Neoplasm Female, Stage I Breast Cancer | Early Phase 1 | Unknown | Institut Català d'Oncologia | 60 | 2018-07-05 | 2021-11-03 |
| Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer TX05 (trastuzumab), Herceptin®, Paclitaxel - Breast Cancer, Breast Neoplasms | Phase 3 | Completed | Tanvex BioPharma USA, Inc. | 809 | 2018-06-28 | 2022-01-14 |
Showing 20 of 120. Sign in to see all of them.
Breast Neoplasms (120) · Carcinoma, Intraductal, Noninfiltrating (16) · Breast Neoplasms, Male (15) · Breast Carcinoma In Situ (11) · Triple Negative Breast Neoplasms (11) · Carcinoma, Ductal, Breast (6) · Depression (6) · Prostatic Neoplasms (6) · Carcinoma, Lobular (5) · Colorectal Neoplasms (5) · Inflammatory Breast Neoplasms (4) · Anxiety Disorders (3) · Peripheral Nervous System Diseases (3) · Neoplasms (2) · Neurotoxicity Syndromes (2)
Breast Diseases (120) · Neoplasms by Site (120) · Skin Diseases (120) · Skin and Connective Tissue Diseases (120) · Neoplasms (118) · Neoplasms by Histologic Type (25) · Carcinoma (24) · Neoplasms, Glandular and Epithelial (24) · Carcinoma in Situ (20) · Adenocarcinoma (19) · Neoplasms, Ductal, Lobular, and Medullary (19) · Breast Carcinoma In Situ (9) · Behavior (8) · Genital Diseases (8) · Pathological Conditions, Signs and Symptoms (8)
Cyclophosphamide (19) · Paclitaxel (16) · Doxorubicin (15) · Taxes (12) · Trastuzumab (11) · Capecitabine (7) · Anastrozole (6) · Carboplatin (6) · Early Intervention, Educational (6) · Letrozole (6) · Magnetic Resonance Spectroscopy (6) · Filgrastim (5) · Granulocyte Colony-Stimulating Factor (5) · Methods (5) · Radiotherapy (5)
University of Southern California (11) · National Cancer Institute (NCI) (10) · University of Washington (10) · Wake Forest University Health Sciences (8) · Dana-Farber Cancer Institute (7) · Case Comprehensive Cancer Center (5) · Alliance for Clinical Trials in Oncology (4) · City of Hope Medical Center (4) · Ohio State University Comprehensive Cancer Center (4) · Northwestern University (3) · Rutgers, The State University of New Jersey (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · Barbara Ann Karmanos Cancer Institute (2) · ECOG-ACRIN Cancer Research Group (2) · Jonsson Comprehensive Cancer Center (2)
United States (108) · Canada (5) · Puerto Rico (4) · Belarus (2) · Chile (2) · China (2) · Georgia (2) · Hungary (2) · India (2) · Japan (2) · Mexico (2) · Peru (2) · Philippines (2) · Russia (2) · Spain (2)
Hannah Linden (3) · Vered Stearns (3) · Adrienne Waks, MD (2) · Bonnie Mills, PhD (2) · Christina Dieli-Conwright, Ph.D. (2) · Dawn Hershman (2) · Dennis Holmes (2) · Jennifer Specht (2) · Agustin Garcia (1) · Agustin Garcia, MD (1) · Alexander Stessin, MD PhD (1) · Aman Buzdar (1) · Amulya C Yellala, MD (1) · Amy Degnim, M.D. (1) · Andrea Barsevick, PhD (1)
PMID 31833973, PMID 37887530, PMID 22827973, PMID 24068539, PMID 24154719, PMID 24210070, PMID 24239210, PMID 24464780, PMID 24708832, PMID 26006067, PMID 26276750, PMID 27520860, PMID 28045625, PMID 28453704, PMID 28560655, PMID 29233615, PMID 29356607, PMID 29440043, PMID 30193295, PMID 30340503, PMID 30549145, PMID 30920602, PMID 30971205, PMID 31309977, PMID 32297442, PMID 33292676, PMID 33740205, PMID 33929533, PMID 34092112, PMID 34413391, PMID 34987618, PMID 35795051, PMID 37946201, PMID 38236590, PMID 38236702, PMID 38300710, PMID 38979716, PMID 40097486, PMID 40314623, PMID 40332918, PMID 40443562, PMID 40466065, PMID 41170811, PMID 42082270
P30CA012197 (4), P30CA014089 (3), P30CA015704 (3), N01CM62204 (2), P30CA014520 (2), P30CA016059 (2), P30CA036727 (2), P30CA072720 (2), U10CA012027 (2), U10CA031946 (2), 2016 (1), N01CM62202 (1), N01CN00033 (1), N01CN35159 (1), P30CA006927 (1)